Skye Bioscience to Join Upcoming Healthcare Investment Conferences
Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biopharmaceutical company dedicated to advancing therapeutic pathways for metabolic health, has announced its participation in several esteemed healthcare investment conferences. These events will allow Skye to highlight its innovative strategies and connect with potential investors.
Participation in Key Conferences
Skye Bioscience's involvement in important healthcare investment conferences is a crucial part of its strategy to engage with the investment community and share its latest developments. The company is scheduled to participate in the following conferences:
Morgan Stanley Conference
On a designated date, Skye will hold one-on-one meetings at the Morgan Stanley healthcare conference, facilitating direct discussions about its progress and future plans.
Cantor Global Healthcare Conference
During the Cantor Global Healthcare Conference, Skye will present at 8:35 AM ET, followed by additional one-on-one meetings to explore the company's upcoming initiatives and clinical trial outcomes in greater detail.
Bank of America World Medical Innovation Forum
Skye will also participate in a panel discussion and engage in one-on-one meetings at the Bank of America World Medical Innovation Forum, further demonstrating its commitment to addressing emerging trends in the healthcare sector.
Company Overview
Skye Bioscience is committed to pioneering new therapeutic pathways for metabolic health by developing next-generation molecules that modulate G-protein coupled receptors. Their approach centers on biologic targets with substantial human evidence of mechanisms, aiming to create first-in-class therapeutics that excel in both clinical efficacy and market potential.
Current Research Projects
The company has recently initiated a Phase 2 clinical trial focused on obesity treatment, assessing the effectiveness of nimacimab, a negative allosteric modulating antibody. This molecule works peripherally to inhibit CB1 and will be evaluated both as a standalone treatment and in conjunction with a GLP-1R agonist.
Innovative Therapeutics Development
Skye's dedication to innovation is reflected in its systematic approach to therapeutic development, ensuring that their candidates possess strong clinical and commercial differentiation.
Contact Information
For any inquiries or investor relations, interested individuals can contact Skye Bioscience directly.
Investor Relations
Contact: ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors
Name: Mike Moyer
Email: mmoyer@lifesciadvisors.com
Phone: (617) 308-4306
Media Inquiries
Contact: Michael Fitzhugh, LifeSci Communications
Email: mfitzhugh@lifescicomms.com
Phone: (628) 234-3889
Frequently Asked Questions
What is Skye Bioscience focusing on during the conferences?
Skye Bioscience aims to present its innovative therapeutic developments and engage with potential investors.
What are the key upcoming events for Skye Bioscience?
Skye will participate in the Morgan Stanley Conference, Cantor Global Healthcare Conference, and the Bank of America Forum.
What is nimacimab and what is its role?
Nimacimab is a negative allosteric modulating antibody that Skye is evaluating in clinical trials for obesity treatment.
How can I contact Skye Bioscience for more information?
You can reach them via their investor relations email at ir@skyebioscience.com or call them at (858) 410-0266.
What therapeutic areas is Skye Bioscience focused on?
Skye is focused on metabolic health and developing treatments that modulate G-protein coupled receptors.